Company
Headquarters: Shijiazhuang, China
Employees: 10,909
CN¥11.07 Billion
CNY as of July 1, 2025
US$1.54 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
North China Pharmaceutical Company Ltd. operates as a chemical pharmaceutical company in China. It primarily offers anti-infective drugs, comprising APIs, and intermediates and their preparations; biotechnology drugs; cardiovascular and immunomodulators; vitamins health consumer products; and bio-agricultural and veterinary drugs. North China Pharmaceutical Company Ltd. was founded in 1953 and is based in Shijiazhuang, China.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥9.89 B |
| EBITDA | CN¥821.6 M |
| Gross Profit TTM | CN¥3.11 B |
| Profit Margin | 1.68% |
| Operating Margin | 6.83% |
| Quarterly Revenue Growth | 0.70% |
North China Pharmaceutical Company Ltd has the following listings and related stock indices.
Stock: SSE: 600812 wb_incandescent